Loading
A phase 3 trial of Percutaneous hepatic perfusion in Uveal melanoma, run by Vastra Gotaland Region, now recruiting.
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases is a phase 3 interventional study registered as NCT06519266 by Vastra Gotaland Region, with 40 participants planned, started 2024-06-10 and due to reach its primary completion in 2028-12-31. Interventions recorded: PHP, IPI1/NIVO3, IPI3/NIVO1. Conditions recorded: Uveal Melanoma, Liver Metastases.
Linked to the technology Percutaneous hepatic perfusion because the registry's title names it ("percutaneous hepatic perfusion") and Uveal melanoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/